Oncopeptides publishes report for Q2 2021
Launch dynamics encouraging, but US regulatory situation challengingSTOCKHOLM — August 19, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the report for the second quarter 2021. Financial overview April-June · Net sales amounted to SEK 66.4 M (0.0) · Operating loss amounted to SEK 344.8 M (loss: 399.3) · Loss for the period was SEK 24.1 M (loss: 401.0) · Loss per share, before and after dilution, was SEK 0.32 (loss: 6.79) · Cash and